Michael J. Campa - Concepedia

Author

Michael J. Campa

Also Known As

M CAMPA, M Campa, M J Campa, M. Campa, M.J. Campa, Michael Campa, Michael J Campa, Michael J. Campa, Monica Diez Campa, O'Reilly, Eileen M.

123

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital University of North Carolina at Chapel Hill Burroughs Wellcome Fund

About

Michael J. Campa is an author at Duke Medical Center specializing in medicine, cell biology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	576
2	Biochemistry	5	5	144
3	Natural Sciences	3	3	81
4	Engineering	2	2	30
5	Health Sciences	1	1	19

Michael J. Campa

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Tumor infiltrating Foxp3<sup>+</sup> regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients Rebecca P. Petersen, Michael J. Campa, Justin Sperlazza, Cancer	2006	432
Panel of Serum Biomarkers for the Diagnosis of Lung Cancer Edward F. Patz, Michael J. Campa, Elizabeth B. Gottlin, Journal of Clinical Oncology	2007	248
Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Michael J. Campa, Michael Z. Wang, Brandon A. Howard, PubMed Lung InflammationImmunologyCancer BiologyTumor BiologyProtein Expression	2003	156
Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression Yu Wang, Shengnan Sun, Qing Liu, Cancer Discovery	2016	156
Identification and validation of a potential lung cancer serum biomarker detected by matrix‐assisted laser desorption/ionization‐time of flight spectra analysis Brandon A. Howard, Michael Z. Wang, Michael J. Campa, PROTEOMICS	2003	122
Stable RNA Interference–Mediated Suppression of Cyclophilin A Diminishes Non–Small-Cell Lung Tumor Growth <i>In vivo</i> Brandon A. Howard, Ryohei Furumai, Michael J. Campa, Cancer Research	2005	94
Haptoglobin and posttranslational glycan‐modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer Luke F. Hoagland, Michael J. Campa, Elizabeth B. Gottlin, Cancer	2007	86
Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC Nita Amornsiripanitch, Shao-lin Hong, Michael J. Campa, Clinical Cancer Research	2010	69
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma Nayela Khan, Charles Cromer, Michael J. Campa, Cancer	2004	65
A Therapeutic Antibody for Cancer, Derived from Single Human B Cells Ryan T. Bushey, M. Anthony Moody, Nathan L. Nicely, Cell Reports	2016	56

Page 1